Open an account

Traws Pharma

TRAW · NASDAQ

$0.3767+$0.0102 (+2.78%)TodayMarket closed ·
Prev close $0.3665

About TRAW

Traws Pharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the identification and development of oncology therapeutics. The company is headquartered in Newtown, Pennsylvania and currently employs 7 full-time employees. The company went IPO on 2013-07-25. The company integrates antiviral drug development, medical intelligence and regulatory strategy in the treatment of viral diseases. The Cadvancing novel investigational oral small-molecule antiviral agents that have potent activity against difficult to treat or resistant virus strains that threaten human health: bird flu and seasonal influenza, and COVID-19/Long COVID. Its four clinical programs consist of Tivoxavir marboxil, Ratutrelvir (TRX0), Narazaciclib, and Rigosertib. Tivoxavir marboxil is a small-molecule cap-dependent endonuclease inhibitor. Ratutrelvir (TRX01) is an inhibitor of the main protease (also known as 3CL protease) of the SARS-CoV-2 virus. arazaciclib is its oral CDK4-plus inhibitor intended initially to treat breast cancers, endometrial and other cancers. Rigosertib is its second asset in oncology.

Employees
7
Headquarters
Newtown, Pennsylvania
Listed
Jul 25, 2013
Sector
Health Care
Industry
Pharmaceuticals
Website
trawspharma.com

TRAW key statistics

Market cap
5.79M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
1.63M
Volume
93.13K
Open price
$0.3807
High today
$0.3854
Low today
$0.3673
52 Week high
$3.23
52 Week low
$0.3601

Traws Pharma (TRAW) at a glance

As of Oct 20, 2026, Traws Pharma (TRAW) shares are priced at $0.3767, giving the company a market cap of 5.79M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.3673 and $0.3854. The current price is 2.6% above the day's low and 2.3% below its high.

Volume so far is 93.13K shares, below the average of 1.63M shares a day.

Over the past year Traws Pharma has ranged from $0.3601 to $3.23, and now sits 1% of the way up that range.

Traws Pharma met or beat analyst EPS estimates in 7 of the last 8 quarters. In Q2 FY26 it reported -$0.25 per share against an estimate of -$0.3422.

The average analyst price target is $1.02, 170.8% above the current price, from 2 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

0%of 2 analyst ratings say Buy
  • Buy0.0%
  • Hold100.0%
  • Sell0.0%
Price target · 3 analystsAvg $1.02
Low
$1.01
Now
$0.3767
High
$1.05

TRAW earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 7 of the last 8 quarters, by 196.5% on average.

  1. Q2 FY23: reported -$5.00 per share against an estimate of -$7.97
  2. Q3 FY23: reported -$5.75 per share against an estimate of -$7.39
  3. Q4 FY23: reported -$4.75 per share against an estimate of -$6.46
  4. Q4 FY24: reported $95.66 per share against an estimate of -$9.74
  5. Q3 FY24: reported -$8.81 per share against an estimate of -$6.25
  6. Q4 FY25: reported $0.63 per share against an estimate of -$1.25
  7. Q1 FY26: reported -$0.53 per share against an estimate of -$0.7548
  8. Q2 FY26: reported -$0.25 per share against an estimate of -$0.3422

TRAW news

  • Avi Kapoor

    Why INLIF Shares Are Trading Higher By Around 78%; Here Are 20 Stocks Moving Premarket

  • Vandana Singh

    Traws Pharma Stock Falls As UK Regulator Delays Key Flu Study

  • Snigdha Gairola

    Chuck Schumer Blasts Trump, Elon Musk For Firing CDC And Port Health Workers As Hantavirus Scare Grips The World

  • 12 Health Care Stocks Moving In Friday's Intraday Session

  • Vandana Singh

    Traws Pharma Gains After Hantavirus Drug Development Update Amid Cruise Ship Outbreak

  • 12 Health Care Stocks Moving In Friday's Pre-Market Session

  • 12 Health Care Stocks Moving In Wednesday's Pre-Market Session

  • 12 Health Care Stocks Moving In Friday's After-Market Session

Similar companies

Companies in the same industry as Traws Pharma

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.